A randomized controlled trial for low-dose continuous Infusion of human atrial natriuretic peptide for cardiac dysfunction undergoing cardiac surgery

A randomized controlled trial for low-dose continuous Infusion of human atrial natriuretic peptide for cardiac dysfunction undergoing cardiac surgery - NU-HIT trial for LVD

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001652

Enrollment

130

Registered

2009-01-23

Start date

1997-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction, angina

Interventions

Perioperative administration of hANP Perioperative non-administration of hANP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Preoperative cardiac dysfunction (ejection fraction<40%) Patient undergoing cardiac surgery Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: cardiogenic shock renal dysfunction with hemodyalysis

Design outcomes

Primary

Measure	Time frame
Early postoperative outcome(mortality and complications) Long-term results(cardiac death-and events-free rate, overall survival rate after surgery))	—

Secondary

Measure	Time frame
cardiac function(UCG, BNP) renal function (sCr,eGFR,Maximum sCr,Increase of Cr,(pre-max. sCr) > 0.3 mg/dl) ANP, renin, anigotensin-II, aldsterone	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026